These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 33856475)

  • 1. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Eneanya ND; Essien U; Julien H; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Netw Open; 2021 Apr; 4(4):e216139. PubMed ID: 33856475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.
    Gregg LP; Ramsey DJ; Akeroyd JM; Jafry SA; Matheny ME; Virani SS; Navaneethan SD
    Am J Kidney Dis; 2023 Jul; 82(1):53-62.e1. PubMed ID: 36702340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation.
    Eberly LA; Garg L; Yang L; Markman TM; Nathan AS; Eneanya ND; Dixit S; Marchlinski FE; Groeneveld PW; Frankel DS
    JAMA Netw Open; 2021 Feb; 4(2):e210247. PubMed ID: 33635328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    Shin JI; Xu Y; Chang AR; Carrero JJ; Flaherty CM; Mukhopadhyay A; Inker LA; Blecker SB; Horwitz LI; Grams ME
    J Am Coll Cardiol; 2024 Aug; 84(8):683-693. PubMed ID: 39142721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease.
    Ozaki AF; Ko DT; Chong A; Fang J; Atzema CL; Austin PC; Stukel TA; Tu K; Udell JA; Naimark D; Booth GL; Jackevicius CA
    CMAJ Open; 2023; 11(3):E494-E503. PubMed ID: 37311594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
    JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States.
    Nathan AS; Geng Z; Dayoub EJ; Khatana SAM; Eberly LA; Kobayashi T; Pugliese SC; Adusumalli S; Giri J; Groeneveld PW
    Circ Cardiovasc Qual Outcomes; 2019 Apr; 12(4):e005600. PubMed ID: 30950652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
    JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.
    Whyte MB; Hinton W; McGovern A; van Vlymen J; Ferreira F; Calderara S; Mount J; Munro N; de Lusignan S
    PLoS Med; 2019 Oct; 16(10):e1002942. PubMed ID: 31589609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study.
    Montvida O; Verma S; Shaw JE; Paul SK
    Diabetes Obes Metab; 2020 Dec; 22(12):2384-2397. PubMed ID: 32744394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
    Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
    JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Characteristics Associated With Telemedicine Access for Primary and Specialty Ambulatory Care During the COVID-19 Pandemic.
    Eberly LA; Kallan MJ; Julien HM; Haynes N; Khatana SAM; Nathan AS; Snider C; Chokshi NP; Eneanya ND; Takvorian SU; Anastos-Wallen R; Chaiyachati K; Ambrose M; O'Quinn R; Seigerman M; Goldberg LR; Leri D; Choi K; Gitelman Y; Kolansky DM; Cappola TP; Ferrari VA; Hanson CW; Deleener ME; Adusumalli S
    JAMA Netw Open; 2020 Dec; 3(12):e2031640. PubMed ID: 33372974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.
    Forbes AK; Hinton W; Feher MD; Elson W; Joy M; Ordóñez-Mena JM; Fan X; Cole NI; Banerjee D; Suckling RJ; de Lusignan S; Swift PA
    EClinicalMedicine; 2024 Feb; 68():102426. PubMed ID: 38304744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes.
    Bermudez SR; Anderson JR; Bos AJ; Ray GM
    Am J Health Syst Pharm; 2023 Dec; 80(24):1787-1795. PubMed ID: 37551996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
    Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.